FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007210860> ?p ?o ?g. }

• W2007210860 endingPage "56" @default.
• W2007210860 startingPage "56" @default.
• W2007210860 abstract "REFER TO THE PAGE 58-63Variant angina pectoris (VAP) is a form of angina pectoris that shows transient ST-segment elevation on electrocardiogram during an attack of chest pain and is caused by coronary artery spasm.1),2) Although the pathogenesis of coronary artery spasm has not been fully elucidated, endothelial dysfunction and enhanced vascular smooth muscle contractility play major roles in the pathogenesis of coronary artery spasm. Other contributing factors of coronary artery spasm include increased oxidative stress, inflammation, magnesium deficiency, genetic susceptibility, and imbalance in autonomic nervous activity.1-3)Statins have been demonstrated to significantly improve the prognosis and outcome of patients with atherosclerosis mainly because statins can lower low density lipoprotein (LDL)-cholesterol concentration.4),5) However, recent studies suggested that statins may affect the cardiovascular system beyond their effect on the lipid profile (called pleiotropic effects).6) Pleiotropic effects of statins include improvement of endothelial dysfunction, increased nitric oxide bioavailability, antioxidant properties, inhibition of inflammatory responses, and stabilization of atherosclerotic plaques, which may provide a cardiovascular benefit beyond that expected from LDL-cholesterol lowering alone.7),8) These effects of modulated endothelial function and reduced inflammatory processes have been pointed out as one of the possible mechanisms of reducing coronary artery vasospasm in VAP.8) Recent clinical evidences also showed that combined therapy with a statin and a calcium channel blocker may attenuate coronary vasoconstriction as well as systemic endothelial dysfunction in patients with VAP.9),10) In this issue of Journal of Cardiovascular Ultrasound, Kim et al.11) also support the evidence that the use of atorvastatin, regardless of dosage, could improve systemic endothelial function as measured by flow mediated dilation of the brachial artery in patients with VAP. Collectively, statin might modify the underlying pathogenesis of coronary artery spasm and be a novel therapeutic drug for coronary artery spasm in patients with VAP.Kim et al.11) also hypothesized that atorvastatin 40 mg could improve more endothelial function and carotid intima media thickness than those of atorvastatin 10 mg. It has not been demonstrated the dose-dependent effects of statin therapy on vascular function in patients with VAP. Experimental studies support this hypothesis that statins can dose-dependently increase the production of nitric oxide by activation of endothelial nitric oxide synthase and increasing its mRNA half-life, independent of cholesterol levels.12),13) Clinical evidence also suggested that intensive lipid-lowering therapy with statin provides significant clinical benefit beyond lipid-lowering therapy in patients with atherosclerosis, which is suggestive of dose-dependent pleiotropic effects of statin.14)However, Kim et al.11) in this issue of J Cardiovasc Ultrasound concluded that the use of high dose statin (atorvastatin 40 mg) did not show significant additional benefit as compared with the use of low dose statin (atorvastatin 10 mg) with regarding carotid intima media thickness and endothelial function. I have some comments about this study. First, atorvastatin 80 mg as a high dose group rather than atorvastatin 40 mg would be a proper dosage for proving additive beneficial effects of endothelial dysfunction and carotid intima media thickness because no clear evidence exists to support additional beneficial effects of medium-dose statin (atorvastatin 40 mg) on vascular function as well as clinical benefits. Second, the study duration is relatively shorter (6 month) for the detection of changes of carotid intima media thickness and flow mediated dilation. These changes of both flow mediated dilation and carotid intima media thickness with statins correlated with the duration × treatment intensity product.15) It needs more than 2 years for the changes of carotid intima media thickness on the progression of carotid atherosclerosis. Finally, the numbers of the study subjects are relatively small to detect the difference of vascular function between atorvastatin 40 mg and atorvastatin 10 mg. In the study of Kim et al.,11) it seems to be more increase of flow mediated dilation in atorvastatin 40 mg group (7.9 ± 2.7% to 9.5 ± 2.8%) than those in atorvastatin 10 mg group (7.7 ± 2.5% to 8.9 ± 2.2%). But, these results were statistically insignificant due to under-powered sample size.Despite some limitations, the present study of Kim et al.11) showed that an addition of statin to the conventional calcium channel blocker and nitrate for 6 months significantly reduced systemic endothelial dysfunction measured by flow mediated dilation in patient with VAP. Statin might be a promising drug for the treatment of VAP." @default.
• W2007210860 created "2016-06-24" @default.
• W2007210860 creator A5007809275 @default.
• W2007210860 date "2013-01-01" @default.
• W2007210860 modified "2023-10-16" @default.
• W2007210860 title "Statins in Variant Angina" @default.
• W2007210860 cites W2014237668 @default.
• W2007210860 cites W2014387652 @default.
• W2007210860 cites W2019039828 @default.
• W2007210860 cites W2029524787 @default.
• W2007210860 cites W2063057223 @default.
• W2007210860 cites W2069518960 @default.
• W2007210860 cites W2074148432 @default.
• W2007210860 cites W2103636227 @default.
• W2007210860 cites W2116999983 @default.
• W2007210860 cites W2118310760 @default.
• W2007210860 cites W2122181287 @default.
• W2007210860 cites W2133534620 @default.
• W2007210860 cites W2150374884 @default.
• W2007210860 cites W2247997571 @default.
• W2007210860 cites W2019463117 @default.
• W2007210860 doi "https://doi.org/10.4250/jcu.2013.21.2.56" @default.
• W2007210860 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3701779" @default.
• W2007210860 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23837114" @default.
• W2007210860 hasPublicationYear "2013" @default.
• W2007210860 type Work @default.
• W2007210860 sameAs 2007210860 @default.
• W2007210860 citedByCount "0" @default.
• W2007210860 crossrefType "journal-article" @default.
• W2007210860 hasAuthorship W2007210860A5007809275 @default.
• W2007210860 hasBestOaLocation W20072108602 @default.
• W2007210860 hasConcept C126322002 @default.
• W2007210860 hasConcept C2778425758 @default.
• W2007210860 hasConcept C500558357 @default.
• W2007210860 hasConcept C71924100 @default.
• W2007210860 hasConceptScore W2007210860C126322002 @default.
• W2007210860 hasConceptScore W2007210860C2778425758 @default.
• W2007210860 hasConceptScore W2007210860C500558357 @default.
• W2007210860 hasConceptScore W2007210860C71924100 @default.
• W2007210860 hasIssue "2" @default.
• W2007210860 hasLocation W20072108601 @default.
• W2007210860 hasLocation W20072108602 @default.
• W2007210860 hasLocation W20072108603 @default.
• W2007210860 hasLocation W20072108604 @default.
• W2007210860 hasOpenAccess W2007210860 @default.
• W2007210860 hasPrimaryLocation W20072108601 @default.
• W2007210860 hasRelatedWork W2027449524 @default.
• W2007210860 hasRelatedWork W2074171729 @default.
• W2007210860 hasRelatedWork W2374518361 @default.
• W2007210860 hasRelatedWork W2379084044 @default.
• W2007210860 hasRelatedWork W2398742161 @default.
• W2007210860 hasRelatedWork W2401218416 @default.
• W2007210860 hasRelatedWork W2411149122 @default.
• W2007210860 hasRelatedWork W2415063993 @default.
• W2007210860 hasRelatedWork W2434854407 @default.
• W2007210860 hasRelatedWork W4236811438 @default.
• W2007210860 hasVolume "21" @default.
• W2007210860 isParatext "false" @default.
• W2007210860 isRetracted "false" @default.
• W2007210860 magId "2007210860" @default.
• W2007210860 workType "article" @default.